B-type Natriuretic Peptide (BNP) in Human Hypertension
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The investigators working hypothesis is that human hypertension is in part due to a
derangement in the endocrine function of the heart - a primary or secondary mechanism -
resulting in a relative deficiency of the natriuretic peptides (NP). The remodeled
hypertensive heart could result in altered processing and degradation of B-type NP resulting
in altered molecular forms with decreased biological activity. The investigators further
hypothesized the chronic administration of BNP in subjects with hypertension, is feasible,
safe and will induce a sustained reduction in blood pressure.